Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ARD-2128 是高效的雄激素受体降解剂 PROTAC。它可有效降低 雄激素受体蛋白并抑制肿瘤组织中雄激素受体调节的基因,在没有毒性迹象的情况下抑制肿瘤生长。它有用于前列腺癌研究的价值。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,320 | 现货 | ||
2 mg | ¥ 3,480 | 现货 | ||
5 mg | ¥ 5,680 | 现货 | ||
10 mg | ¥ 7,950 | 现货 | ||
25 mg | ¥ 11,800 | 现货 | ||
50 mg | ¥ 15,900 | 现货 | ||
100 mg | ¥ 21,300 | 现货 |
产品描述 | ARD-2128 is a highly potent, orally bioavailable PROTAC (proteolysis-targeting chimera) degrader of the androgen receptor (AR), effectively diminishing AR protein levels, suppressing AR-regulated gene expression in tumor tissues, and inhibiting tumor growth without evident toxicity. This compound holds promise for prostate cancer research. |
靶点活性 | LNCaP cells:5 μM (IC50), VCaP:4 nM (IC50) |
体外活性 | ARD-2128 is highly potent and effective in the inhibition of cell growth in the VCaP cell line and LNCaP cell line with the IC 50 values of 4 nM and 5 nM, respectively [1]. ARD-2128 (1, 10, 100, and 1000 nM; 24 hours; in VCaP cell) effectively reduces the AR protein level by >50% at 1 nM and achieves the AR degradation of >90% at 10, 100, and 1000 nM, respectively[1] . Cell Viability Assay [1] Cell Line: VCaP cell Concentration: 1, 10, 100, and 1000 nM Incubation Time: 24 hours Result: Reduces the AR protein level and achieves the AR degradation. |
体内活性 | ARD-2128 (20 mg/kg; p.o.; once) is effective in reducing the level of AR protein in mice after 24 hours [1]. ARD-2128 (10-40 mg/kg; p.o.; daily for 21 days) shows antitumor activity in the VCaP xenograft model in mice [1] . ARD-2128 (5mg/kg; p.o.) treatment shows the C max , AUC 0-t and t 1/2 values of 1304 ng/mL, 22361 ng h/mL and 18.8 hours, respectively [1] . Animal Model: SCID mice [1] Dosage: 20 mg/kg Administration: Oral Result: Reducing the level of AR protein in mice after 24 hours. Animal Model: SCID mice [1] Dosage: 10, 20, and 40 mg/kg Administration: P.o.; daily for 21 days Result: Inhibits tumor growth by 46, 69, and 63%, respectively. Animal Model: Male ICR Mice [1] Dosage: 5 mg/kg Administration: P.o. (Pharmacokinetic Analysis) Result: The C max , AUC 0-t and t 1/2 were 1304 ng/mL, 22361 ng h/mL and 18.8 hours, respectively. ARD-2128 achieves 67% oral bioavailability in mice, effectively reduces AR protein and suppresses AR-regulated genes in tumor tissues with oral administration, leading to the effective inhibition of tumor growth in mice without signs of toxicity. |
分子量 | 820.37 |
分子式 | C45H50ClN7O6 |
CAS No. | 2222111-87-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (121.90 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.219 mL | 6.0948 mL | 12.1896 mL | 30.4741 mL |
5 mM | 0.2438 mL | 1.219 mL | 2.4379 mL | 6.0948 mL | |
10 mM | 0.1219 mL | 0.6095 mL | 1.219 mL | 3.0474 mL | |
20 mM | 0.0609 mL | 0.3047 mL | 0.6095 mL | 1.5237 mL | |
50 mM | 0.0244 mL | 0.1219 mL | 0.2438 mL | 0.6095 mL | |
100 mM | 0.0122 mL | 0.0609 mL | 0.1219 mL | 0.3047 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ARD-2128 2222111-87-5 Endocrinology/Hormones Androgen Receptor orally AR-regulated bioavailable inhibit Inhibitor prostate ARD2128 cancer tumor ARD 2128 PROTACs inhibitor